SHR-1501

DRUG3 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.

Conditions

Advanced MalignanciesHigh-risk NMIBC

Phase 1

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

CompletedNCT03995472

Jiangsu HengRui Medicine Co., Ltd.Advanced Malignancies

Start: 2020-02-14End: 2023-01-12Updated: 2023-09-28

A Study of SHR-1501 in Patients With Advanced Tumors

CompletedNCT04025957

Jiangsu HengRui Medicine Co., Ltd.Advanced Malignancies

Start: 2019-10-30End: 2022-07-31Updated: 2023-09-28

A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC

RecruitingNCT05410730

Shanghai Hengrui Pharmaceutical Co., Ltd.High-risk NMIBC

Start: 2022-11-23End: 2027-05-31Target: 150Updated: 2025-01-28

Related Papers

IL-15RαFc superagonist SHR-1501 with or without bacille Calmette Guerin (BCG) for high-risk non-muscle invasive bladder cancer (NMIBC): A phase 1/2 study.

Journal of Clinical Oncology2025-05-28